nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—UGT1A1—Mycophenolic acid—psoriasis	0.0762	0.159	CbGbCtD
Nilotinib—UGT1A1—Mycophenolate mofetil—psoriasis	0.0426	0.089	CbGbCtD
Nilotinib—CYP2C8—Tazarotene—psoriasis	0.0337	0.0705	CbGbCtD
Nilotinib—ABCG2—Mycophenolate mofetil—psoriasis	0.0234	0.049	CbGbCtD
Nilotinib—CYP2B6—Cholecalciferol—psoriasis	0.019	0.0397	CbGbCtD
Nilotinib—ABCG2—Hydrocortisone—psoriasis	0.0188	0.0393	CbGbCtD
Nilotinib—ABCG2—Cyclosporine—psoriasis	0.0177	0.0371	CbGbCtD
Nilotinib—CYP2D6—Hydroxyurea—psoriasis	0.0151	0.0317	CbGbCtD
Nilotinib—CYP2C8—Cholecalciferol—psoriasis	0.0144	0.0301	CbGbCtD
Nilotinib—CYP2C8—Mycophenolate mofetil—psoriasis	0.0125	0.0261	CbGbCtD
Nilotinib—ABCG2—Dexamethasone—psoriasis	0.0117	0.0244	CbGbCtD
Nilotinib—CYP3A4—Calcitriol—psoriasis	0.0113	0.0237	CbGbCtD
Nilotinib—CYP2C9—Cholecalciferol—psoriasis	0.01	0.021	CbGbCtD
Nilotinib—CYP2C8—Hydrocortisone—psoriasis	0.01	0.0209	CbGbCtD
Nilotinib—CYP2C8—Cyclosporine—psoriasis	0.00945	0.0198	CbGbCtD
Nilotinib—ABCG2—Methotrexate—psoriasis	0.00939	0.0196	CbGbCtD
Nilotinib—CYP2D6—Cholecalciferol—psoriasis	0.00917	0.0192	CbGbCtD
Nilotinib—CYP3A4—Methoxsalen—psoriasis	0.0088	0.0184	CbGbCtD
Nilotinib—ABCB1—Mycophenolate mofetil—psoriasis	0.00844	0.0177	CbGbCtD
Nilotinib—CYP2B6—Dexamethasone—psoriasis	0.00822	0.0172	CbGbCtD
Nilotinib—ABCB1—Betamethasone—psoriasis	0.00724	0.0152	CbGbCtD
Nilotinib—ABCB1—Prednisolone—psoriasis	0.00714	0.0149	CbGbCtD
Nilotinib—ABCB1—Hydrocortisone—psoriasis	0.00677	0.0142	CbGbCtD
Nilotinib—ABCB1—Prednisone—psoriasis	0.00675	0.0141	CbGbCtD
Nilotinib—CYP2C9—Cyclosporine—psoriasis	0.00659	0.0138	CbGbCtD
Nilotinib—ABCB1—Cyclosporine—psoriasis	0.0064	0.0134	CbGbCtD
Nilotinib—CYP2C8—Dexamethasone—psoriasis	0.00622	0.013	CbGbCtD
Nilotinib—CYP2D6—Cyclosporine—psoriasis	0.00603	0.0126	CbGbCtD
Nilotinib—CYP3A4—Cholecalciferol—psoriasis	0.00583	0.0122	CbGbCtD
Nilotinib—MAPK8—skin epidermis—psoriasis	0.00571	0.116	CbGeAlD
Nilotinib—CYP3A4—Mycophenolate mofetil—psoriasis	0.00506	0.0106	CbGbCtD
Nilotinib—CYP3A4—Triamcinolone—psoriasis	0.00506	0.0106	CbGbCtD
Nilotinib—CYP2C9—Dexamethasone—psoriasis	0.00434	0.00908	CbGbCtD
Nilotinib—CYP3A4—Betamethasone—psoriasis	0.00434	0.00908	CbGbCtD
Nilotinib—CYP3A4—Prednisolone—psoriasis	0.00428	0.00896	CbGbCtD
Nilotinib—ABCB1—Dexamethasone—psoriasis	0.00421	0.00881	CbGbCtD
Nilotinib—MAPK8—endothelium—psoriasis	0.00415	0.084	CbGeAlD
Nilotinib—CYP3A4—Hydrocortisone—psoriasis	0.00406	0.00849	CbGbCtD
Nilotinib—CYP3A4—Prednisone—psoriasis	0.00404	0.00846	CbGbCtD
Nilotinib—CYP2D6—Dexamethasone—psoriasis	0.00397	0.0083	CbGbCtD
Nilotinib—CYP3A4—Cyclosporine—psoriasis	0.00383	0.00802	CbGbCtD
Nilotinib—TIE1—endothelium—psoriasis	0.0036	0.0728	CbGeAlD
Nilotinib—ABCB1—Methotrexate—psoriasis	0.00338	0.00708	CbGbCtD
Nilotinib—CYP3A4—Dexamethasone—psoriasis	0.00252	0.00528	CbGbCtD
Nilotinib—EPHB4—endothelium—psoriasis	0.0025	0.0505	CbGeAlD
Nilotinib—TEK—endothelium—psoriasis	0.00239	0.0484	CbGeAlD
Nilotinib—KIT—skin epidermis—psoriasis	0.00238	0.0483	CbGeAlD
Nilotinib—MAPK8—skin of body—psoriasis	0.00177	0.0358	CbGeAlD
Nilotinib—KIT—endothelium—psoriasis	0.00173	0.035	CbGeAlD
Nilotinib—CDC42BPB—tendon—psoriasis	0.00149	0.0302	CbGeAlD
Nilotinib—MAPK8—tendon—psoriasis	0.00135	0.0273	CbGeAlD
Nilotinib—MAP4K1—tendon—psoriasis	0.00122	0.0248	CbGeAlD
Nilotinib—MAPK14—skin of body—psoriasis	0.00112	0.0228	CbGeAlD
Nilotinib—BRAF—tendon—psoriasis	0.00112	0.0227	CbGeAlD
Nilotinib—HCK—tendon—psoriasis	0.00102	0.0207	CbGeAlD
Nilotinib—ABL2—tendon—psoriasis	0.00102	0.0205	CbGeAlD
Nilotinib—EPHB6—skin of body—psoriasis	0.000975	0.0197	CbGeAlD
Nilotinib—EPHA4—tendon—psoriasis	0.000928	0.0188	CbGeAlD
Nilotinib—CA3—tendon—psoriasis	0.000917	0.0186	CbGeAlD
Nilotinib—CA9—tendon—psoriasis	0.000878	0.0178	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Clobetasol propionate—psoriasis	0.000863	0.195	CbGdCrCtD
Nilotinib—MAPK14—tendon—psoriasis	0.000856	0.0173	CbGeAlD
Nilotinib—FGR—tendon—psoriasis	0.000853	0.0173	CbGeAlD
Nilotinib—CA14—tendon—psoriasis	0.000833	0.0169	CbGeAlD
Nilotinib—CSF1R—skin of body—psoriasis	0.000814	0.0165	CbGeAlD
Nilotinib—EPHB4—tendon—psoriasis	0.000811	0.0164	CbGeAlD
Nilotinib—EPHA2—tendon—psoriasis	0.000796	0.0161	CbGeAlD
Nilotinib—TEK—tendon—psoriasis	0.000777	0.0157	CbGeAlD
Nilotinib—EPHB6—tendon—psoriasis	0.000742	0.015	CbGeAlD
Nilotinib—KIT—skin of body—psoriasis	0.000739	0.015	CbGeAlD
Nilotinib—PDGFRB—skin of body—psoriasis	0.000722	0.0146	CbGeAlD
Nilotinib—PDGFRA—tendon—psoriasis	0.000704	0.0142	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Beclomethasone—psoriasis	0.000691	0.156	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Fluocinonide—psoriasis	0.000691	0.156	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Fluocinolone Acetonide—psoriasis	0.000672	0.152	CbGdCrCtD
Nilotinib—ABL1—skin of body—psoriasis	0.000643	0.013	CbGeAlD
Nilotinib—MAP2K5—tendon—psoriasis	0.000635	0.0128	CbGeAlD
Nilotinib—CSF1R—tendon—psoriasis	0.000619	0.0125	CbGeAlD
Nilotinib—PDGFRB—tendon—psoriasis	0.000549	0.0111	CbGeAlD
Nilotinib—ABL1—tendon—psoriasis	0.00049	0.00991	CbGeAlD
Nilotinib—CA2—skin of body—psoriasis	0.000438	0.00887	CbGeAlD
Nilotinib—CA4—tendon—psoriasis	0.000402	0.00814	CbGeAlD
Nilotinib—CYP2B6—skin of body—psoriasis	0.000374	0.00758	CbGeAlD
Nilotinib—CA2—tendon—psoriasis	0.000333	0.00675	CbGeAlD
Nilotinib—EPHB2—Diflorasone—Dexamethasone—psoriasis	0.000315	0.0711	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Betamethasone—psoriasis	0.000315	0.0711	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Triamcinolone—psoriasis	0.000308	0.0694	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Prednisone—psoriasis	0.000292	0.0659	CbGdCrCtD
Nilotinib—EPHB2—Diflorasone—Prednisolone—psoriasis	0.000285	0.0643	CbGdCrCtD
Nilotinib—Anxiety—Dexamethasone—psoriasis	4.99e-05	0.000176	CcSEcCtD
Nilotinib—Anxiety—Betamethasone—psoriasis	4.99e-05	0.000176	CcSEcCtD
Nilotinib—Vomiting—Mycophenolic acid—psoriasis	4.97e-05	0.000176	CcSEcCtD
Nilotinib—Discomfort—Dexamethasone—psoriasis	4.95e-05	0.000175	CcSEcCtD
Nilotinib—Discomfort—Betamethasone—psoriasis	4.95e-05	0.000175	CcSEcCtD
Nilotinib—Dyspepsia—Hydrocortisone—psoriasis	4.95e-05	0.000175	CcSEcCtD
Nilotinib—Haemoglobin—Methotrexate—psoriasis	4.95e-05	0.000175	CcSEcCtD
Nilotinib—Rash—Mycophenolic acid—psoriasis	4.93e-05	0.000174	CcSEcCtD
Nilotinib—Dermatitis—Mycophenolic acid—psoriasis	4.93e-05	0.000174	CcSEcCtD
Nilotinib—Pain—Prednisolone—psoriasis	4.92e-05	0.000174	CcSEcCtD
Nilotinib—Haemorrhage—Methotrexate—psoriasis	4.92e-05	0.000174	CcSEcCtD
Nilotinib—Hepatitis—Methotrexate—psoriasis	4.92e-05	0.000174	CcSEcCtD
Nilotinib—Urticaria—Mycophenolate mofetil—psoriasis	4.9e-05	0.000173	CcSEcCtD
Nilotinib—Headache—Mycophenolic acid—psoriasis	4.9e-05	0.000173	CcSEcCtD
Nilotinib—Decreased appetite—Hydrocortisone—psoriasis	4.89e-05	0.000173	CcSEcCtD
Nilotinib—Pharyngitis—Methotrexate—psoriasis	4.88e-05	0.000173	CcSEcCtD
Nilotinib—Abdominal pain—Mycophenolate mofetil—psoriasis	4.88e-05	0.000172	CcSEcCtD
Nilotinib—Body temperature increased—Mycophenolate mofetil—psoriasis	4.88e-05	0.000172	CcSEcCtD
Nilotinib—Urinary tract disorder—Methotrexate—psoriasis	4.86e-05	0.000172	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.85e-05	0.000171	CcSEcCtD
Nilotinib—Fatigue—Hydrocortisone—psoriasis	4.85e-05	0.000171	CcSEcCtD
Nilotinib—Vision blurred—Prednisone—psoriasis	4.83e-05	0.000171	CcSEcCtD
Nilotinib—Urethral disorder—Methotrexate—psoriasis	4.82e-05	0.00017	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.82e-05	0.00017	CcSEcCtD
Nilotinib—Pain—Hydrocortisone—psoriasis	4.81e-05	0.00017	CcSEcCtD
Nilotinib—Oedema—Dexamethasone—psoriasis	4.8e-05	0.00017	CcSEcCtD
Nilotinib—Oedema—Betamethasone—psoriasis	4.8e-05	0.00017	CcSEcCtD
Nilotinib—Insomnia—Triamcinolone—psoriasis	4.79e-05	0.000169	CcSEcCtD
Nilotinib—Infection—Betamethasone—psoriasis	4.77e-05	0.000169	CcSEcCtD
Nilotinib—Infection—Dexamethasone—psoriasis	4.77e-05	0.000169	CcSEcCtD
Nilotinib—Ill-defined disorder—Prednisone—psoriasis	4.76e-05	0.000168	CcSEcCtD
Nilotinib—Paraesthesia—Triamcinolone—psoriasis	4.75e-05	0.000168	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisolone—psoriasis	4.74e-05	0.000168	CcSEcCtD
Nilotinib—Visual impairment—Methotrexate—psoriasis	4.74e-05	0.000168	CcSEcCtD
Nilotinib—Anaemia—Prednisone—psoriasis	4.74e-05	0.000167	CcSEcCtD
Nilotinib—Shock—Betamethasone—psoriasis	4.73e-05	0.000167	CcSEcCtD
Nilotinib—Shock—Dexamethasone—psoriasis	4.73e-05	0.000167	CcSEcCtD
Nilotinib—Dyspnoea—Triamcinolone—psoriasis	4.72e-05	0.000167	CcSEcCtD
Nilotinib—Nervous system disorder—Betamethasone—psoriasis	4.71e-05	0.000166	CcSEcCtD
Nilotinib—Nervous system disorder—Dexamethasone—psoriasis	4.71e-05	0.000166	CcSEcCtD
Nilotinib—Thrombocytopenia—Betamethasone—psoriasis	4.7e-05	0.000166	CcSEcCtD
Nilotinib—Thrombocytopenia—Dexamethasone—psoriasis	4.7e-05	0.000166	CcSEcCtD
Nilotinib—Tachycardia—Dexamethasone—psoriasis	4.69e-05	0.000166	CcSEcCtD
Nilotinib—Tachycardia—Betamethasone—psoriasis	4.69e-05	0.000166	CcSEcCtD
Nilotinib—Hypersensitivity—Cyclosporine—psoriasis	4.66e-05	0.000165	CcSEcCtD
Nilotinib—Dyspepsia—Triamcinolone—psoriasis	4.66e-05	0.000165	CcSEcCtD
Nilotinib—Erythema multiforme—Methotrexate—psoriasis	4.65e-05	0.000164	CcSEcCtD
Nilotinib—Nausea—Mycophenolic acid—psoriasis	4.64e-05	0.000164	CcSEcCtD
Nilotinib—Hyperhidrosis—Betamethasone—psoriasis	4.64e-05	0.000164	CcSEcCtD
Nilotinib—Hyperhidrosis—Dexamethasone—psoriasis	4.64e-05	0.000164	CcSEcCtD
Nilotinib—Feeling abnormal—Hydrocortisone—psoriasis	4.63e-05	0.000164	CcSEcCtD
Nilotinib—Malaise—Prednisone—psoriasis	4.62e-05	0.000163	CcSEcCtD
Nilotinib—Vertigo—Prednisone—psoriasis	4.6e-05	0.000163	CcSEcCtD
Nilotinib—Eye disorder—Methotrexate—psoriasis	4.6e-05	0.000162	CcSEcCtD
Nilotinib—Gastrointestinal pain—Hydrocortisone—psoriasis	4.6e-05	0.000162	CcSEcCtD
Nilotinib—Syncope—Prednisone—psoriasis	4.6e-05	0.000162	CcSEcCtD
Nilotinib—Tinnitus—Methotrexate—psoriasis	4.59e-05	0.000162	CcSEcCtD
Nilotinib—Anorexia—Betamethasone—psoriasis	4.58e-05	0.000162	CcSEcCtD
Nilotinib—Anorexia—Dexamethasone—psoriasis	4.58e-05	0.000162	CcSEcCtD
Nilotinib—Urticaria—Prednisolone—psoriasis	4.57e-05	0.000162	CcSEcCtD
Nilotinib—Cardiac disorder—Methotrexate—psoriasis	4.57e-05	0.000161	CcSEcCtD
Nilotinib—Fatigue—Triamcinolone—psoriasis	4.56e-05	0.000161	CcSEcCtD
Nilotinib—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.55e-05	0.000161	CcSEcCtD
Nilotinib—Asthenia—Cyclosporine—psoriasis	4.54e-05	0.00016	CcSEcCtD
Nilotinib—Pain—Triamcinolone—psoriasis	4.53e-05	0.00016	CcSEcCtD
Nilotinib—Loss of consciousness—Prednisone—psoriasis	4.5e-05	0.000159	CcSEcCtD
Nilotinib—Hypotension—Dexamethasone—psoriasis	4.49e-05	0.000159	CcSEcCtD
Nilotinib—Hypotension—Betamethasone—psoriasis	4.49e-05	0.000159	CcSEcCtD
Nilotinib—Pruritus—Cyclosporine—psoriasis	4.48e-05	0.000158	CcSEcCtD
Nilotinib—Urticaria—Hydrocortisone—psoriasis	4.47e-05	0.000158	CcSEcCtD
Nilotinib—Angiopathy—Methotrexate—psoriasis	4.46e-05	0.000158	CcSEcCtD
Nilotinib—Immune system disorder—Methotrexate—psoriasis	4.44e-05	0.000157	CcSEcCtD
Nilotinib—Abdominal pain—Hydrocortisone—psoriasis	4.44e-05	0.000157	CcSEcCtD
Nilotinib—Body temperature increased—Hydrocortisone—psoriasis	4.44e-05	0.000157	CcSEcCtD
Nilotinib—Mediastinal disorder—Methotrexate—psoriasis	4.43e-05	0.000157	CcSEcCtD
Nilotinib—Asthenia—Mycophenolate mofetil—psoriasis	4.43e-05	0.000156	CcSEcCtD
Nilotinib—Hypertension—Prednisone—psoriasis	4.42e-05	0.000156	CcSEcCtD
Nilotinib—Chills—Methotrexate—psoriasis	4.41e-05	0.000156	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Betamethasone—psoriasis	4.38e-05	0.000155	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.38e-05	0.000155	CcSEcCtD
Nilotinib—Pruritus—Mycophenolate mofetil—psoriasis	4.37e-05	0.000154	CcSEcCtD
Nilotinib—Arthralgia—Prednisone—psoriasis	4.36e-05	0.000154	CcSEcCtD
Nilotinib—Myalgia—Prednisone—psoriasis	4.36e-05	0.000154	CcSEcCtD
Nilotinib—Feeling abnormal—Triamcinolone—psoriasis	4.36e-05	0.000154	CcSEcCtD
Nilotinib—Anxiety—Prednisone—psoriasis	4.35e-05	0.000154	CcSEcCtD
Nilotinib—Alopecia—Methotrexate—psoriasis	4.35e-05	0.000154	CcSEcCtD
Nilotinib—Insomnia—Betamethasone—psoriasis	4.34e-05	0.000153	CcSEcCtD
Nilotinib—Insomnia—Dexamethasone—psoriasis	4.34e-05	0.000153	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4.33e-05	0.000153	CcSEcCtD
Nilotinib—Diarrhoea—Cyclosporine—psoriasis	4.33e-05	0.000153	CcSEcCtD
Nilotinib—Paraesthesia—Betamethasone—psoriasis	4.31e-05	0.000152	CcSEcCtD
Nilotinib—Paraesthesia—Dexamethasone—psoriasis	4.31e-05	0.000152	CcSEcCtD
Nilotinib—Discomfort—Prednisone—psoriasis	4.31e-05	0.000152	CcSEcCtD
Nilotinib—Mental disorder—Methotrexate—psoriasis	4.31e-05	0.000152	CcSEcCtD
Nilotinib—Malnutrition—Methotrexate—psoriasis	4.28e-05	0.000151	CcSEcCtD
Nilotinib—Erythema—Methotrexate—psoriasis	4.28e-05	0.000151	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisolone—psoriasis	4.24e-05	0.00015	CcSEcCtD
Nilotinib—Dyspepsia—Betamethasone—psoriasis	4.23e-05	0.000149	CcSEcCtD
Nilotinib—Dyspepsia—Dexamethasone—psoriasis	4.23e-05	0.000149	CcSEcCtD
Nilotinib—Diarrhoea—Mycophenolate mofetil—psoriasis	4.22e-05	0.000149	CcSEcCtD
Nilotinib—Urticaria—Triamcinolone—psoriasis	4.21e-05	0.000149	CcSEcCtD
Nilotinib—Dysgeusia—Methotrexate—psoriasis	4.19e-05	0.000148	CcSEcCtD
Nilotinib—Body temperature increased—Triamcinolone—psoriasis	4.18e-05	0.000148	CcSEcCtD
Nilotinib—Dizziness—Cyclosporine—psoriasis	4.18e-05	0.000148	CcSEcCtD
Nilotinib—Oedema—Prednisone—psoriasis	4.18e-05	0.000148	CcSEcCtD
Nilotinib—Decreased appetite—Dexamethasone—psoriasis	4.18e-05	0.000148	CcSEcCtD
Nilotinib—Decreased appetite—Betamethasone—psoriasis	4.18e-05	0.000148	CcSEcCtD
Nilotinib—Infection—Prednisone—psoriasis	4.16e-05	0.000147	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Betamethasone—psoriasis	4.15e-05	0.000147	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Dexamethasone—psoriasis	4.15e-05	0.000147	CcSEcCtD
Nilotinib—Back pain—Methotrexate—psoriasis	4.14e-05	0.000146	CcSEcCtD
Nilotinib—Hypersensitivity—Hydrocortisone—psoriasis	4.14e-05	0.000146	CcSEcCtD
Nilotinib—Fatigue—Dexamethasone—psoriasis	4.14e-05	0.000146	CcSEcCtD
Nilotinib—Fatigue—Betamethasone—psoriasis	4.14e-05	0.000146	CcSEcCtD
Nilotinib—Shock—Prednisone—psoriasis	4.12e-05	0.000145	CcSEcCtD
Nilotinib—Pain—Dexamethasone—psoriasis	4.11e-05	0.000145	CcSEcCtD
Nilotinib—Pain—Betamethasone—psoriasis	4.11e-05	0.000145	CcSEcCtD
Nilotinib—Nervous system disorder—Prednisone—psoriasis	4.1e-05	0.000145	CcSEcCtD
Nilotinib—Tachycardia—Prednisone—psoriasis	4.08e-05	0.000144	CcSEcCtD
Nilotinib—Dizziness—Mycophenolate mofetil—psoriasis	4.08e-05	0.000144	CcSEcCtD
Nilotinib—Skin disorder—Prednisone—psoriasis	4.06e-05	0.000144	CcSEcCtD
Nilotinib—Hyperhidrosis—Prednisone—psoriasis	4.04e-05	0.000143	CcSEcCtD
Nilotinib—Vision blurred—Methotrexate—psoriasis	4.04e-05	0.000143	CcSEcCtD
Nilotinib—Asthenia—Hydrocortisone—psoriasis	4.03e-05	0.000143	CcSEcCtD
Nilotinib—Vomiting—Cyclosporine—psoriasis	4.02e-05	0.000142	CcSEcCtD
Nilotinib—Rash—Cyclosporine—psoriasis	3.99e-05	0.000141	CcSEcCtD
Nilotinib—Anorexia—Prednisone—psoriasis	3.99e-05	0.000141	CcSEcCtD
Nilotinib—Dermatitis—Cyclosporine—psoriasis	3.98e-05	0.000141	CcSEcCtD
Nilotinib—Pruritus—Hydrocortisone—psoriasis	3.98e-05	0.000141	CcSEcCtD
Nilotinib—Ill-defined disorder—Methotrexate—psoriasis	3.97e-05	0.00014	CcSEcCtD
Nilotinib—Headache—Cyclosporine—psoriasis	3.96e-05	0.00014	CcSEcCtD
Nilotinib—Anaemia—Methotrexate—psoriasis	3.96e-05	0.00014	CcSEcCtD
Nilotinib—Feeling abnormal—Betamethasone—psoriasis	3.96e-05	0.00014	CcSEcCtD
Nilotinib—Feeling abnormal—Dexamethasone—psoriasis	3.96e-05	0.00014	CcSEcCtD
Nilotinib—Gastrointestinal pain—Dexamethasone—psoriasis	3.93e-05	0.000139	CcSEcCtD
Nilotinib—Gastrointestinal pain—Betamethasone—psoriasis	3.93e-05	0.000139	CcSEcCtD
Nilotinib—Vomiting—Mycophenolate mofetil—psoriasis	3.92e-05	0.000139	CcSEcCtD
Nilotinib—Hypersensitivity—Triamcinolone—psoriasis	3.9e-05	0.000138	CcSEcCtD
Nilotinib—Rash—Mycophenolate mofetil—psoriasis	3.89e-05	0.000137	CcSEcCtD
Nilotinib—Dermatitis—Mycophenolate mofetil—psoriasis	3.89e-05	0.000137	CcSEcCtD
Nilotinib—Headache—Mycophenolate mofetil—psoriasis	3.87e-05	0.000137	CcSEcCtD
Nilotinib—Malaise—Methotrexate—psoriasis	3.86e-05	0.000136	CcSEcCtD
Nilotinib—Vertigo—Methotrexate—psoriasis	3.85e-05	0.000136	CcSEcCtD
Nilotinib—Diarrhoea—Hydrocortisone—psoriasis	3.85e-05	0.000136	CcSEcCtD
Nilotinib—Leukopenia—Methotrexate—psoriasis	3.83e-05	0.000135	CcSEcCtD
Nilotinib—Urticaria—Dexamethasone—psoriasis	3.82e-05	0.000135	CcSEcCtD
Nilotinib—Urticaria—Betamethasone—psoriasis	3.82e-05	0.000135	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Prednisone—psoriasis	3.81e-05	0.000135	CcSEcCtD
Nilotinib—Dizziness—Prednisolone—psoriasis	3.81e-05	0.000134	CcSEcCtD
Nilotinib—Asthenia—Triamcinolone—psoriasis	3.8e-05	0.000134	CcSEcCtD
Nilotinib—Abdominal pain—Betamethasone—psoriasis	3.8e-05	0.000134	CcSEcCtD
Nilotinib—Body temperature increased—Dexamethasone—psoriasis	3.8e-05	0.000134	CcSEcCtD
Nilotinib—Abdominal pain—Dexamethasone—psoriasis	3.8e-05	0.000134	CcSEcCtD
Nilotinib—Body temperature increased—Betamethasone—psoriasis	3.8e-05	0.000134	CcSEcCtD
Nilotinib—Insomnia—Prednisone—psoriasis	3.78e-05	0.000134	CcSEcCtD
Nilotinib—Nausea—Cyclosporine—psoriasis	3.76e-05	0.000133	CcSEcCtD
Nilotinib—Paraesthesia—Prednisone—psoriasis	3.76e-05	0.000133	CcSEcCtD
Nilotinib—Pruritus—Triamcinolone—psoriasis	3.75e-05	0.000132	CcSEcCtD
Nilotinib—Cough—Methotrexate—psoriasis	3.74e-05	0.000132	CcSEcCtD
Nilotinib—Dizziness—Hydrocortisone—psoriasis	3.72e-05	0.000131	CcSEcCtD
Nilotinib—Dyspepsia—Prednisone—psoriasis	3.68e-05	0.00013	CcSEcCtD
Nilotinib—Nausea—Mycophenolate mofetil—psoriasis	3.67e-05	0.00013	CcSEcCtD
Nilotinib—Myalgia—Methotrexate—psoriasis	3.65e-05	0.000129	CcSEcCtD
Nilotinib—Chest pain—Methotrexate—psoriasis	3.65e-05	0.000129	CcSEcCtD
Nilotinib—Arthralgia—Methotrexate—psoriasis	3.65e-05	0.000129	CcSEcCtD
Nilotinib—Decreased appetite—Prednisone—psoriasis	3.64e-05	0.000128	CcSEcCtD
Nilotinib—Rash—Prednisolone—psoriasis	3.63e-05	0.000128	CcSEcCtD
Nilotinib—Dermatitis—Prednisolone—psoriasis	3.63e-05	0.000128	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.62e-05	0.000128	CcSEcCtD
Nilotinib—Fatigue—Prednisone—psoriasis	3.61e-05	0.000127	CcSEcCtD
Nilotinib—Headache—Prednisolone—psoriasis	3.61e-05	0.000127	CcSEcCtD
Nilotinib—Discomfort—Methotrexate—psoriasis	3.6e-05	0.000127	CcSEcCtD
Nilotinib—Constipation—Prednisone—psoriasis	3.58e-05	0.000126	CcSEcCtD
Nilotinib—Vomiting—Hydrocortisone—psoriasis	3.57e-05	0.000126	CcSEcCtD
Nilotinib—Rash—Hydrocortisone—psoriasis	3.54e-05	0.000125	CcSEcCtD
Nilotinib—Dermatitis—Hydrocortisone—psoriasis	3.54e-05	0.000125	CcSEcCtD
Nilotinib—Confusional state—Methotrexate—psoriasis	3.52e-05	0.000125	CcSEcCtD
Nilotinib—Headache—Hydrocortisone—psoriasis	3.52e-05	0.000124	CcSEcCtD
Nilotinib—Dizziness—Triamcinolone—psoriasis	3.5e-05	0.000124	CcSEcCtD
Nilotinib—Infection—Methotrexate—psoriasis	3.47e-05	0.000123	CcSEcCtD
Nilotinib—Feeling abnormal—Prednisone—psoriasis	3.45e-05	0.000122	CcSEcCtD
Nilotinib—Asthenia—Betamethasone—psoriasis	3.45e-05	0.000122	CcSEcCtD
Nilotinib—Asthenia—Dexamethasone—psoriasis	3.45e-05	0.000122	CcSEcCtD
Nilotinib—Nervous system disorder—Methotrexate—psoriasis	3.43e-05	0.000121	CcSEcCtD
Nilotinib—Thrombocytopenia—Methotrexate—psoriasis	3.42e-05	0.000121	CcSEcCtD
Nilotinib—Gastrointestinal pain—Prednisone—psoriasis	3.42e-05	0.000121	CcSEcCtD
Nilotinib—Nausea—Prednisolone—psoriasis	3.42e-05	0.000121	CcSEcCtD
Nilotinib—Pruritus—Dexamethasone—psoriasis	3.4e-05	0.00012	CcSEcCtD
Nilotinib—Pruritus—Betamethasone—psoriasis	3.4e-05	0.00012	CcSEcCtD
Nilotinib—Skin disorder—Methotrexate—psoriasis	3.4e-05	0.00012	CcSEcCtD
Nilotinib—Hyperhidrosis—Methotrexate—psoriasis	3.38e-05	0.000119	CcSEcCtD
Nilotinib—Vomiting—Triamcinolone—psoriasis	3.37e-05	0.000119	CcSEcCtD
Nilotinib—Nausea—Hydrocortisone—psoriasis	3.34e-05	0.000118	CcSEcCtD
Nilotinib—Rash—Triamcinolone—psoriasis	3.34e-05	0.000118	CcSEcCtD
Nilotinib—Dermatitis—Triamcinolone—psoriasis	3.33e-05	0.000118	CcSEcCtD
Nilotinib—Anorexia—Methotrexate—psoriasis	3.33e-05	0.000118	CcSEcCtD
Nilotinib—Urticaria—Prednisone—psoriasis	3.32e-05	0.000117	CcSEcCtD
Nilotinib—Headache—Triamcinolone—psoriasis	3.32e-05	0.000117	CcSEcCtD
Nilotinib—Abdominal pain—Prednisone—psoriasis	3.31e-05	0.000117	CcSEcCtD
Nilotinib—Body temperature increased—Prednisone—psoriasis	3.31e-05	0.000117	CcSEcCtD
Nilotinib—Diarrhoea—Dexamethasone—psoriasis	3.29e-05	0.000116	CcSEcCtD
Nilotinib—Diarrhoea—Betamethasone—psoriasis	3.29e-05	0.000116	CcSEcCtD
Nilotinib—Hypotension—Methotrexate—psoriasis	3.27e-05	0.000115	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Methotrexate—psoriasis	3.18e-05	0.000113	CcSEcCtD
Nilotinib—Dizziness—Dexamethasone—psoriasis	3.18e-05	0.000112	CcSEcCtD
Nilotinib—Dizziness—Betamethasone—psoriasis	3.18e-05	0.000112	CcSEcCtD
Nilotinib—Insomnia—Methotrexate—psoriasis	3.16e-05	0.000112	CcSEcCtD
Nilotinib—Nausea—Triamcinolone—psoriasis	3.14e-05	0.000111	CcSEcCtD
Nilotinib—Paraesthesia—Methotrexate—psoriasis	3.14e-05	0.000111	CcSEcCtD
Nilotinib—Dyspnoea—Methotrexate—psoriasis	3.12e-05	0.00011	CcSEcCtD
Nilotinib—Hypersensitivity—Prednisone—psoriasis	3.08e-05	0.000109	CcSEcCtD
Nilotinib—Dyspepsia—Methotrexate—psoriasis	3.08e-05	0.000109	CcSEcCtD
Nilotinib—Vomiting—Betamethasone—psoriasis	3.05e-05	0.000108	CcSEcCtD
Nilotinib—Vomiting—Dexamethasone—psoriasis	3.05e-05	0.000108	CcSEcCtD
Nilotinib—Decreased appetite—Methotrexate—psoriasis	3.04e-05	0.000107	CcSEcCtD
Nilotinib—Rash—Betamethasone—psoriasis	3.03e-05	0.000107	CcSEcCtD
Nilotinib—Rash—Dexamethasone—psoriasis	3.03e-05	0.000107	CcSEcCtD
Nilotinib—Dermatitis—Dexamethasone—psoriasis	3.03e-05	0.000107	CcSEcCtD
Nilotinib—Dermatitis—Betamethasone—psoriasis	3.03e-05	0.000107	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Methotrexate—psoriasis	3.02e-05	0.000107	CcSEcCtD
Nilotinib—Fatigue—Methotrexate—psoriasis	3.01e-05	0.000106	CcSEcCtD
Nilotinib—Headache—Betamethasone—psoriasis	3.01e-05	0.000106	CcSEcCtD
Nilotinib—Headache—Dexamethasone—psoriasis	3.01e-05	0.000106	CcSEcCtD
Nilotinib—Asthenia—Prednisone—psoriasis	3e-05	0.000106	CcSEcCtD
Nilotinib—Pain—Methotrexate—psoriasis	2.99e-05	0.000106	CcSEcCtD
Nilotinib—Pruritus—Prednisone—psoriasis	2.96e-05	0.000105	CcSEcCtD
Nilotinib—Feeling abnormal—Methotrexate—psoriasis	2.88e-05	0.000102	CcSEcCtD
Nilotinib—Diarrhoea—Prednisone—psoriasis	2.86e-05	0.000101	CcSEcCtD
Nilotinib—Gastrointestinal pain—Methotrexate—psoriasis	2.86e-05	0.000101	CcSEcCtD
Nilotinib—Nausea—Dexamethasone—psoriasis	2.85e-05	0.000101	CcSEcCtD
Nilotinib—Nausea—Betamethasone—psoriasis	2.85e-05	0.000101	CcSEcCtD
Nilotinib—Urticaria—Methotrexate—psoriasis	2.78e-05	9.81e-05	CcSEcCtD
Nilotinib—Dizziness—Prednisone—psoriasis	2.77e-05	9.77e-05	CcSEcCtD
Nilotinib—Body temperature increased—Methotrexate—psoriasis	2.76e-05	9.76e-05	CcSEcCtD
Nilotinib—Abdominal pain—Methotrexate—psoriasis	2.76e-05	9.76e-05	CcSEcCtD
Nilotinib—Vomiting—Prednisone—psoriasis	2.66e-05	9.4e-05	CcSEcCtD
Nilotinib—Rash—Prednisone—psoriasis	2.64e-05	9.32e-05	CcSEcCtD
Nilotinib—Dermatitis—Prednisone—psoriasis	2.63e-05	9.31e-05	CcSEcCtD
Nilotinib—Headache—Prednisone—psoriasis	2.62e-05	9.26e-05	CcSEcCtD
Nilotinib—Hypersensitivity—Methotrexate—psoriasis	2.58e-05	9.1e-05	CcSEcCtD
Nilotinib—Asthenia—Methotrexate—psoriasis	2.51e-05	8.86e-05	CcSEcCtD
Nilotinib—Nausea—Prednisone—psoriasis	2.48e-05	8.78e-05	CcSEcCtD
Nilotinib—Pruritus—Methotrexate—psoriasis	2.47e-05	8.74e-05	CcSEcCtD
Nilotinib—Diarrhoea—Methotrexate—psoriasis	2.39e-05	8.45e-05	CcSEcCtD
Nilotinib—Dizziness—Methotrexate—psoriasis	2.31e-05	8.17e-05	CcSEcCtD
Nilotinib—Vomiting—Methotrexate—psoriasis	2.22e-05	7.85e-05	CcSEcCtD
Nilotinib—Rash—Methotrexate—psoriasis	2.2e-05	7.79e-05	CcSEcCtD
Nilotinib—Dermatitis—Methotrexate—psoriasis	2.2e-05	7.78e-05	CcSEcCtD
Nilotinib—Headache—Methotrexate—psoriasis	2.19e-05	7.74e-05	CcSEcCtD
Nilotinib—Nausea—Methotrexate—psoriasis	2.08e-05	7.34e-05	CcSEcCtD
Nilotinib—FGR—Immune System—STAT3—psoriasis	8.17e-06	4.41e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NFKBIA—psoriasis	8.13e-06	4.39e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NOS2—psoriasis	8.09e-06	4.37e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-A—psoriasis	8.08e-06	4.36e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP2S1—psoriasis	8.06e-06	4.35e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SOCS1—psoriasis	8.06e-06	4.35e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—JUN—psoriasis	8e-06	4.32e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—TYK2—psoriasis	7.96e-06	4.3e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—LEP—psoriasis	7.9e-06	4.27e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—APOE—psoriasis	7.9e-06	4.27e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IFNG—psoriasis	7.88e-06	4.25e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.87e-06	4.25e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—TNF—psoriasis	7.84e-06	4.23e-05	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—IL6—psoriasis	7.83e-06	4.23e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—APOE—psoriasis	7.83e-06	4.23e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—LEP—psoriasis	7.83e-06	4.23e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—TYK2—psoriasis	7.77e-06	4.19e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—VEGFA—psoriasis	7.76e-06	4.19e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—CD4—psoriasis	7.72e-06	4.17e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CRP—psoriasis	7.71e-06	4.16e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—NFKB1—psoriasis	7.7e-06	4.16e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SOCS1—psoriasis	7.64e-06	4.13e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—CD4—psoriasis	7.61e-06	4.11e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	7.6e-06	4.1e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TYK2—psoriasis	7.57e-06	4.09e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—PPARG—psoriasis	7.55e-06	4.08e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—JUN—psoriasis	7.55e-06	4.08e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—HLA-A—psoriasis	7.46e-06	4.03e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IFNG—psoriasis	7.46e-06	4.02e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—NFKB1—psoriasis	7.39e-06	3.99e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HLA-DRB1—psoriasis	7.38e-06	3.98e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NFKBIA—psoriasis	7.36e-06	3.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—TYK2—psoriasis	7.35e-06	3.97e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CARM1—psoriasis	7.34e-06	3.96e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NFKBIA—psoriasis	7.29e-06	3.94e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—CAT—psoriasis	7.27e-06	3.93e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—NFKB1—psoriasis	7.27e-06	3.92e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—CD4—psoriasis	7.2e-06	3.89e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TYK2—psoriasis	7.2e-06	3.89e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—TYK2—psoriasis	7.17e-06	3.87e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—psoriasis	7.16e-06	3.86e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—LEP—psoriasis	7.12e-06	3.85e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—APOE—psoriasis	7.12e-06	3.85e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—psoriasis	7.12e-06	3.85e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—ICAM1—psoriasis	7.08e-06	3.82e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—IL6—psoriasis	7.06e-06	3.81e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NFKBIA—psoriasis	7.03e-06	3.79e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—CD4—psoriasis	7.02e-06	3.79e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—TYK2—psoriasis	7.02e-06	3.79e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—TYK2—psoriasis	6.99e-06	3.77e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—APOE—psoriasis	6.96e-06	3.76e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.86e-06	3.7e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—JUN—psoriasis	6.81e-06	3.68e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—psoriasis	6.78e-06	3.66e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—LEP—psoriasis	6.74e-06	3.64e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—APOE—psoriasis	6.74e-06	3.64e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IFNG—psoriasis	6.72e-06	3.63e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	6.7e-06	3.62e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—IL6—psoriasis	6.69e-06	3.61e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—IL6—psoriasis	6.68e-06	3.6e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—APOE—psoriasis	6.66e-06	3.59e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—TYK2—psoriasis	6.66e-06	3.59e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—CD4—psoriasis	6.65e-06	3.59e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—IL6—psoriasis	6.65e-06	3.59e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NFKBIA—psoriasis	6.64e-06	3.58e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—TYK2—psoriasis	6.62e-06	3.58e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SOCS1—psoriasis	6.61e-06	3.57e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—CXCL8—psoriasis	6.59e-06	3.56e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IFNG—psoriasis	6.58e-06	3.55e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—NFKB1—psoriasis	6.55e-06	3.54e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IFNG—psoriasis	6.55e-06	3.53e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—STAT3—psoriasis	6.53e-06	3.53e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NOS2—psoriasis	6.49e-06	3.5e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—CD4—psoriasis	6.49e-06	3.5e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—JUN—psoriasis	6.44e-06	3.48e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.41e-06	3.46e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CARM1—psoriasis	6.39e-06	3.45e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—CD4—psoriasis	6.35e-06	3.43e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—IL6—psoriasis	6.33e-06	3.42e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—CD4—psoriasis	6.32e-06	3.41e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—IL6—psoriasis	6.32e-06	3.41e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NFKBIA—psoriasis	6.28e-06	3.39e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—CXCL8—psoriasis	6.27e-06	3.38e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IFNG—psoriasis	6.23e-06	3.37e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NFKB1—psoriasis	6.2e-06	3.35e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—JUN—psoriasis	6.13e-06	3.31e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—APOE—psoriasis	6.08e-06	3.28e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—LEP—psoriasis	6.08e-06	3.28e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TYK2—psoriasis	6.03e-06	3.26e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—IL6—psoriasis	6.02e-06	3.25e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CARM1—psoriasis	6.02e-06	3.25e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—CD4—psoriasis	6.02e-06	3.25e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—CD4—psoriasis	5.99e-06	3.23e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TYK2—psoriasis	5.97e-06	3.23e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—STAT3—psoriasis	5.97e-06	3.23e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CARM1—psoriasis	5.97e-06	3.22e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—LEP—psoriasis	5.95e-06	3.21e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—APOE—psoriasis	5.95e-06	3.21e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NFKB1—psoriasis	5.9e-06	3.18e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—IL6—psoriasis	5.9e-06	3.18e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—STAT3—psoriasis	5.89e-06	3.18e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—IL6—psoriasis	5.87e-06	3.17e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—psoriasis	5.87e-06	3.17e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—IL6—psoriasis	5.83e-06	3.15e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—JUN—psoriasis	5.83e-06	3.14e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—JUN—psoriasis	5.81e-06	3.13e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PPARG—psoriasis	5.8e-06	3.13e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—TYK2—psoriasis	5.76e-06	3.11e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—IL6—psoriasis	5.73e-06	3.09e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—IL6—psoriasis	5.73e-06	3.09e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—IL6—psoriasis	5.71e-06	3.08e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—JUN—psoriasis	5.68e-06	3.07e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NFKBIA—psoriasis	5.66e-06	3.06e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—JUN—psoriasis	5.66e-06	3.05e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—APOE—psoriasis	5.65e-06	3.05e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—LEP—psoriasis	5.64e-06	3.04e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—APOE—psoriasis	5.64e-06	3.04e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NFKB1—psoriasis	5.61e-06	3.03e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—IL6—psoriasis	5.59e-06	3.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NFKB1—psoriasis	5.59e-06	3.02e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.58e-06	3.01e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—STAT3—psoriasis	5.57e-06	3.01e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NFKBIA—psoriasis	5.54e-06	2.99e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—NFKB1—psoriasis	5.47e-06	2.95e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NFKB1—psoriasis	5.45e-06	2.94e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TYK2—psoriasis	5.44e-06	2.94e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—STAT3—psoriasis	5.44e-06	2.94e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IFNG—psoriasis	5.39e-06	2.91e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—JUN—psoriasis	5.39e-06	2.91e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—VEGFA—psoriasis	5.35e-06	2.89e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—CAT—psoriasis	5.33e-06	2.88e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—TYK2—psoriasis	5.31e-06	2.87e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—STAT3—psoriasis	5.3e-06	2.86e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NFKBIA—psoriasis	5.25e-06	2.84e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—CXCL8—psoriasis	5.25e-06	2.83e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—CD4—psoriasis	5.21e-06	2.81e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—CXCL8—psoriasis	5.2e-06	2.81e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NFKB1—psoriasis	5.19e-06	2.8e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TYK2—psoriasis	5.15e-06	2.78e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—STAT3—psoriasis	5.15e-06	2.78e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—VEGFA—psoriasis	5.09e-06	2.75e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—STAT3—psoriasis	5.04e-06	2.72e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—STAT3—psoriasis	5.02e-06	2.71e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PPARG—psoriasis	4.92e-06	2.66e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—STAT3—psoriasis	4.92e-06	2.65e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—STAT3—psoriasis	4.89e-06	2.64e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—JUN—psoriasis	4.88e-06	2.64e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—LEP—psoriasis	4.88e-06	2.63e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—APOE—psoriasis	4.88e-06	2.63e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—JUN—psoriasis	4.84e-06	2.61e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—IL6—psoriasis	4.83e-06	2.61e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—CD4—psoriasis	4.81e-06	2.59e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—CXCL8—psoriasis	4.73e-06	2.56e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NFKB1—psoriasis	4.7e-06	2.54e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—STAT3—psoriasis	4.66e-06	2.52e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—JUN—psoriasis	4.66e-06	2.52e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NFKB1—psoriasis	4.65e-06	2.51e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TYK2—psoriasis	4.64e-06	2.5e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—STAT3—psoriasis	4.64e-06	2.5e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—IL6—psoriasis	4.56e-06	2.46e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NFKBIA—psoriasis	4.54e-06	2.45e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TYK2—psoriasis	4.54e-06	2.45e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CAT—psoriasis	4.51e-06	2.44e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NFKB1—psoriasis	4.48e-06	2.42e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—CXCL8—psoriasis	4.48e-06	2.42e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—JUN—psoriasis	4.4e-06	2.38e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TYK2—psoriasis	4.3e-06	2.32e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—VEGFA—psoriasis	4.26e-06	2.3e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NFKB1—psoriasis	4.24e-06	2.29e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—VEGFA—psoriasis	4.22e-06	2.28e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—STAT3—psoriasis	4.22e-06	2.28e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—STAT3—psoriasis	4.18e-06	2.26e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—IL6—psoriasis	4.17e-06	2.25e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—JUN—psoriasis	4.17e-06	2.25e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—APOE—psoriasis	4.14e-06	2.24e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—IL6—psoriasis	4.11e-06	2.22e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—psoriasis	4.04e-06	2.18e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CXCL8—psoriasis	4.04e-06	2.18e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—STAT3—psoriasis	4.03e-06	2.18e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NFKB1—psoriasis	4.01e-06	2.17e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CXCL8—psoriasis	3.95e-06	2.13e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CARM1—psoriasis	3.94e-06	2.13e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAT—psoriasis	3.93e-06	2.12e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—psoriasis	3.89e-06	2.1e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—psoriasis	3.85e-06	2.08e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—psoriasis	3.85e-06	2.08e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—psoriasis	3.81e-06	2.06e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—psoriasis	3.8e-06	2.05e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—JUN—psoriasis	3.75e-06	2.03e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—psoriasis	3.75e-06	2.02e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TYK2—psoriasis	3.72e-06	2.01e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—psoriasis	3.72e-06	2.01e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAT—psoriasis	3.7e-06	2e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—psoriasis	3.7e-06	2e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—JUN—psoriasis	3.68e-06	1.98e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAT—psoriasis	3.67e-06	1.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—psoriasis	3.64e-06	1.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NFKB1—psoriasis	3.61e-06	1.95e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PPARG—psoriasis	3.61e-06	1.95e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—psoriasis	3.6e-06	1.95e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—psoriasis	3.6e-06	1.94e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NFKB1—psoriasis	3.54e-06	1.91e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—psoriasis	3.52e-06	1.9e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—psoriasis	3.51e-06	1.89e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—APOE—psoriasis	3.51e-06	1.89e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—JUN—psoriasis	3.48e-06	1.88e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—psoriasis	3.43e-06	1.85e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—psoriasis	3.42e-06	1.85e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NFKB1—psoriasis	3.35e-06	1.81e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—psoriasis	3.28e-06	1.77e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—psoriasis	3.26e-06	1.76e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—psoriasis	3.25e-06	1.75e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—psoriasis	3.24e-06	1.75e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—psoriasis	3.24e-06	1.75e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—psoriasis	3.22e-06	1.74e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—psoriasis	3.21e-06	1.73e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—psoriasis	3.19e-06	1.72e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—psoriasis	3.18e-06	1.72e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—APOE—psoriasis	3.05e-06	1.65e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PPARG—psoriasis	3.05e-06	1.65e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—psoriasis	3.04e-06	1.64e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—psoriasis	3.01e-06	1.63e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—JUN—psoriasis	3.01e-06	1.63e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—psoriasis	2.95e-06	1.59e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—psoriasis	2.92e-06	1.58e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—psoriasis	2.91e-06	1.57e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NFKB1—psoriasis	2.9e-06	1.57e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—APOE—psoriasis	2.88e-06	1.55e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—APOE—psoriasis	2.85e-06	1.54e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—psoriasis	2.82e-06	1.52e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—psoriasis	2.75e-06	1.48e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PPARG—psoriasis	2.66e-06	1.44e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—psoriasis	2.66e-06	1.44e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—psoriasis	2.63e-06	1.42e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—psoriasis	2.61e-06	1.41e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—psoriasis	2.6e-06	1.4e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—psoriasis	2.52e-06	1.36e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPARG—psoriasis	2.51e-06	1.35e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPARG—psoriasis	2.49e-06	1.34e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—psoriasis	2.48e-06	1.34e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—psoriasis	2.43e-06	1.31e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAT—psoriasis	2.42e-06	1.31e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—psoriasis	2.3e-06	1.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—psoriasis	2.27e-06	1.22e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—psoriasis	2.22e-06	1.2e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—psoriasis	2.11e-06	1.14e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—psoriasis	1.99e-06	1.07e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—APOE—psoriasis	1.88e-06	1.02e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—psoriasis	1.82e-06	9.83e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPARG—psoriasis	1.64e-06	8.85e-06	CbGpPWpGaD
